Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
PCI-29732 is a multi-kinase inhibitor.1 It inhibits the Tec family kinase BTK and the Src family kinases LCK and LYN (Kis = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM. PCI-29732 inhibits calcium flux in Ramos B cells and phosphorylation of phospholipase Cɣ1 (PLCɣ1) with IC50 values of 0.53 and 0.33 µM, respectively. It is cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC50s = 7.8, 6.3, and 6.02 µM, respectively).2 PCI-29732 (20 mg/kg), in combination with the DNA topoisomerase I inhibitor topotecan (Item No. 14129), reduces tumor growth in an H460/MX20 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2(1), 58-61 (2007).
2. PCI29732, a Bruton’s tyrosine kinase inhibitor, enhanced the efficacy of conventional chemotherapeutic agents in ABCG2-